FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053180816> ?p ?o ?g. }

• W2053180816 endingPage "235" @default.
• W2053180816 startingPage "227" @default.
• W2053180816 abstract "The aim of this study was to determine the maximum-tolerated dose, of a pre-targeting three-step (3-S) method employing 90Y-biotin in the locoregional radioimmunotherapy (RIT) of recurrent high grade glioma, and to investigate the antitumor efficacy of this new treatment. Twenty-four patients with recurrent glioma underwent second surgical debulking and implantation of a catheter into the surgical resection cavity (SRC), in order to introduce the radioimmunotherapeutic agents [biotinylated monoclonal antibody (MoAb), avidin and 90Y-biotin]. Eight patients with anaplastic astrocytoma (AA) and 16 patients with glioblastoma (GBM) were injected with biotinylated anti-tenascin MoAb (2 mg), then with avidin (10 mg; 24 h later) and finally 90Y-biotin (18 h later). Each patient received two of these treatments 8-10 weeks apart. The injected activity ranged from 0.555 to 1.110 GBq (15-30 mCi). Dosage was escalated by 0.185 GBq (5 mCi) in four consecutive groups. The treatment was well tolerated without acute side effects up to 0.740 GBq (20 mCi). The maximum tolerated activity was 1.110 GBq (30 mCi) limited by neurological toxicity. None of the patients developed hematologic toxicity. In three patients infection occurred around the catheter. The average absorbed dose to the normal brain was minimal compared with that received at the SRC interface. At first control (after 2 months), partial (PR) and minor (MR) responses were observed in three GBM (1 PR; 2 MR) and three AA patients (1 PR; 2 MR) with an overall objective response rate of 25%. Stable disease (SD) was achieved in seven GBM and five AA patients (50%). There was disease progression in six GBM patients (25%), but in none of the AA patients. At the dosage of 0.7-0.9 GBq per cycle, locoregional 3-S-RIT was safe and produced an objective response in 25% of patients. Based on these encouraging results, phase II studies employing 3-S-RIT soon after first debulking are justified." @default.
• W2053180816 created "2016-06-24" @default.
• W2053180816 creator A5013104556 @default.
• W2053180816 creator A5016187996 @default.
• W2053180816 creator A5017138113 @default.
• W2053180816 creator A5025628907 @default.
• W2053180816 creator A5025873393 @default.
• W2053180816 creator A5028569565 @default.
• W2053180816 creator A5042452114 @default.
• W2053180816 creator A5052020344 @default.
• W2053180816 creator A5061171599 @default.
• W2053180816 creator A5064728742 @default.
• W2053180816 creator A5075346036 @default.
• W2053180816 creator A5091844302 @default.
• W2053180816 date "2001-06-01" @default.
• W2053180816 modified "2023-10-15" @default.
• W2053180816 title "Pre-Targeted Locoregional Radioimmunotherapy with ⁹⁰Y-biotin in Glioma Patients: Phase I Study and Preliminary Therapeutic Results" @default.
• W2053180816 cites W1972784935 @default.
• W2053180816 cites W1987408132 @default.
• W2053180816 cites W1995563574 @default.
• W2053180816 cites W1996673454 @default.
• W2053180816 cites W2005710435 @default.
• W2053180816 cites W2025799338 @default.
• W2053180816 cites W2032869728 @default.
• W2053180816 cites W2056173512 @default.
• W2053180816 cites W2059435192 @default.
• W2053180816 cites W2063536977 @default.
• W2053180816 cites W2076592032 @default.
• W2053180816 cites W2088454377 @default.
• W2053180816 cites W2088685259 @default.
• W2053180816 cites W2093920455 @default.
• W2053180816 cites W2109523793 @default.
• W2053180816 cites W2138223287 @default.
• W2053180816 cites W2140098095 @default.
• W2053180816 cites W2177127358 @default.
• W2053180816 cites W4206593204 @default.
• W2053180816 doi "https://doi.org/10.1089/10849780152389410" @default.
• W2053180816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11471487" @default.
• W2053180816 hasPublicationYear "2001" @default.
• W2053180816 type Work @default.
• W2053180816 sameAs 2053180816 @default.
• W2053180816 citedByCount "121" @default.
• W2053180816 countsByYear W20531808162012 @default.
• W2053180816 countsByYear W20531808162013 @default.
• W2053180816 countsByYear W20531808162014 @default.
• W2053180816 countsByYear W20531808162015 @default.
• W2053180816 countsByYear W20531808162016 @default.
• W2053180816 countsByYear W20531808162017 @default.
• W2053180816 countsByYear W20531808162018 @default.
• W2053180816 countsByYear W20531808162019 @default.
• W2053180816 countsByYear W20531808162020 @default.
• W2053180816 countsByYear W20531808162021 @default.
• W2053180816 countsByYear W20531808162022 @default.
• W2053180816 countsByYear W20531808162023 @default.
• W2053180816 crossrefType "journal-article" @default.
• W2053180816 hasAuthorship W2053180816A5013104556 @default.
• W2053180816 hasAuthorship W2053180816A5016187996 @default.
• W2053180816 hasAuthorship W2053180816A5017138113 @default.
• W2053180816 hasAuthorship W2053180816A5025628907 @default.
• W2053180816 hasAuthorship W2053180816A5025873393 @default.
• W2053180816 hasAuthorship W2053180816A5028569565 @default.
• W2053180816 hasAuthorship W2053180816A5042452114 @default.
• W2053180816 hasAuthorship W2053180816A5052020344 @default.
• W2053180816 hasAuthorship W2053180816A5061171599 @default.
• W2053180816 hasAuthorship W2053180816A5064728742 @default.
• W2053180816 hasAuthorship W2053180816A5075346036 @default.
• W2053180816 hasAuthorship W2053180816A5091844302 @default.
• W2053180816 hasConcept C126322002 @default.
• W2053180816 hasConcept C159654299 @default.
• W2053180816 hasConcept C197934379 @default.
• W2053180816 hasConcept C203014093 @default.
• W2053180816 hasConcept C2776146153 @default.
• W2053180816 hasConcept C2778227246 @default.
• W2053180816 hasConcept C2778375690 @default.
• W2053180816 hasConcept C29730261 @default.
• W2053180816 hasConcept C2989005 @default.
• W2053180816 hasConcept C502942594 @default.
• W2053180816 hasConcept C542903549 @default.
• W2053180816 hasConcept C71924100 @default.
• W2053180816 hasConcept C90924648 @default.
• W2053180816 hasConceptScore W2053180816C126322002 @default.
• W2053180816 hasConceptScore W2053180816C159654299 @default.
• W2053180816 hasConceptScore W2053180816C197934379 @default.
• W2053180816 hasConceptScore W2053180816C203014093 @default.
• W2053180816 hasConceptScore W2053180816C2776146153 @default.
• W2053180816 hasConceptScore W2053180816C2778227246 @default.
• W2053180816 hasConceptScore W2053180816C2778375690 @default.
• W2053180816 hasConceptScore W2053180816C29730261 @default.
• W2053180816 hasConceptScore W2053180816C2989005 @default.
• W2053180816 hasConceptScore W2053180816C502942594 @default.
• W2053180816 hasConceptScore W2053180816C542903549 @default.
• W2053180816 hasConceptScore W2053180816C71924100 @default.
• W2053180816 hasConceptScore W2053180816C90924648 @default.
• W2053180816 hasIssue "3" @default.
• W2053180816 hasLocation W20531808161 @default.
• W2053180816 hasLocation W20531808162 @default.
• W2053180816 hasOpenAccess W2053180816 @default.
• W2053180816 hasPrimaryLocation W20531808161 @default.

• next